The primary objective of this study is to evaluate the pharmacokinetic (PK) profile of AMG 510 alone and in combination with rifampin in healthy participants.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
Enrollment
14
Covance Clinical Research Unit, Inc 3402 Kinsman Boulevard
Madison, Wisconsin, United States
Maximum Plasma Concentration (Cmax) of AMG 510
Time frame: Days 1, 3 and 8
Area Under the Plasma Concentration-time Curve (AUC) from Time Zero to Time of Last Quantifiable Concentration (AUClast) of AMG 510
Time frame: Days 1, 3 and 8
AUC from Time Zero to Infinity (AUCinf) of AMG 510
Time frame: Days 1, 3 and 8
Number of Participants with an Adverse Event (AE)
An AE is any untoward medical occurrence in a clinical study participant irrespective of a causal relationship with the study treatment. Any clinically significant changes in clinical laboratory tests, 12-lead electrocardiograms and vital signs will be recorded as AEs .
Time frame: Day 1 to Day 20
Cmax of AMG 510 Metabolite M24
Time frame: Days 1, 3 and 8
AUClast of AMG 510 Metabolite M24
Time frame: Days 1, 3 and 8
AUCinf of AMG 510 Metabolite M24
Time frame: Days 1, 3 and 8
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.